Despite continuing Covid curveballs, licencing and sales income, especially from pain relief product Maxigesic, has lifted earnings for Kiwi drug maker AFT Pharmaceuticals in unaudited half-year results announced today.
For the six months to September 30, the dual-listed company reported a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
